Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging

BACKGROUND: A critical and as-yet unmet need in Alzheimer disease (AD) research is the development of novel markers that can identify individuals at risk for cognitive decline due to AD. This would aid intervention trials designed to slow the progression of AD by increasing diagnostic certainty, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Motsinger-Reif, Alison A, Zhu, Hongjie, Kling, Mitchel A, Matson, Wayne, Sharma, Swati, Fiehn, Oliver, Reif, David M, Appleby, Dina H, Doraiswamy, P Murali, Trojanowski, John Q, Kaddurah-Daouk, Rima, Arnold, Steven E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893491/
https://www.ncbi.nlm.nih.gov/pubmed/24252434
http://dx.doi.org/10.1186/2051-5960-1-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893491/
https://www.ncbi.nlm.nih.gov/pubmed/24252434
http://dx.doi.org/10.1186/2051-5960-1-28

Ejemplares similares